Dear stakeholders and fellow shareholders In response to your many recent inquiries let me review where we stand at the onset of this new year. The company is and has been very much active, looking to revive its medical automation business after many lean years. It still holds a portfolio of valuable intellectual property regarding prevention of adverse drug events (ADE) as well as workflow solutions in the in- patient clinical setting.
Since 2017 we have taken advantage of the fact that our university affiliates are world leaders in machine learning and Artificial intelligence. We are in the process of bringing our applications up to date with artificial intelligence as well as new advances in big data analysis. The medical planning is being done in Montreal, programming will be outsourced to a Polish company for obvious benefit in terms of quality and cost-saving. We are also in the process of taking our intelligent applications originally created for clinicians and making them available to patients and citizens concerned about their health.
This initiative has significant government support. We have been qualified for public funding in the amounts of 2- 2,25M most of which is made of government loans and grants. The main reason for our set back between 2011 and 2016 had been a major shift in government priorities away from seeking better outcomes and reducing deadly adverse drug events to a single-minded focus on the issue of insurance and access to care. Of course, access is an important issue but not one that benefit our clinical improvement business. Now that the issue of access has been resolved there is a renewed interest in finding solutions to our deteriorating quality of care.
After 20 years of massive investments in all kinds of information technology, mostly obsolete, by health boards and hospitals, the number of deadly ADEs, adverse drug events, has not decreased in the United States and Canada. Every year half a million people continue to die from preventable adverse drug event because the combination of prescriptions is not properly monitored neither by physicians nor pharmacists. It remains the same number of preventable deaths that had been referenced in the watershed 1999 National Institute of Health report titled: “To Err is Human”. VisualMED is now turning to new advances in artificial intelligence and machine learning and possibly eventually blockchain. This makes it possible for us to put in the hands of individual patients, the very same technology tools that they can now use to monitor their own health status and to some extent monitor their prescriptions and procedures. A we know most people are not health conscious, but we believe we can rebuild our business around mothers with children, people caring about aging parents and, yes perhaps, hypochondriacs. A few hundred thousand subscribers could support a viable business model. We shall see. With my best wishes for a Happy New year Gérard Dab
